Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Supernus Pharm (SUPN)

Supernus Pharm (SUPN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,970,160
  • Shares Outstanding, K 57,339
  • Annual Sales, $ 661,820 K
  • Annual Income, $ 73,870 K
  • EBIT $ 46 M
  • EBITDA $ 128 M
  • 60-Month Beta 0.67
  • Price/Sales 4.27
  • Price/Cash Flow 12.31
  • Price/Book 2.81

Options Overview Details

View History
  • Implied Volatility 43.62% (-1.31%)
  • Historical Volatility 25.63%
  • IV Percentile 37%
  • IV Rank 35.61%
  • IV High 79.59% on 01/30/25
  • IV Low 23.73% on 06/11/25
  • Expected Move (DTE 1) 2.27 (4.38%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 6
  • Volume Avg (30-Day) 181
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 3,491
  • Open Int (30-Day) 3,187
  • Expected Range 49.53 to 54.07

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.15
  • Number of Estimates 1
  • High Estimate 0.15
  • Low Estimate 0.15
  • Prior Year 0.61
  • Growth Rate Est. (year over year) -75.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
46.76 +10.77%
on 12/15/25
52.50 -1.33%
on 01/12/26
+4.64 (+9.84%)
since 12/12/25
3-Month
43.11 +20.16%
on 11/05/25
57.65 -10.15%
on 10/30/25
+2.58 (+5.24%)
since 10/14/25
52-Week
29.16 +77.64%
on 05/07/25
57.65 -10.15%
on 10/30/25
+13.98 (+36.96%)
since 01/14/25

Most Recent Stories

More News
3 Low-Volatility Stocks We’re Skeptical Of

3 Low-Volatility Stocks We’re Skeptical Of

LKQ : 33.27 (-0.15%)
WABC : 48.52 (+0.31%)
SUPN : 51.80 (+0.68%)
3 of Wall Street’s Favorite Stocks That Concern Us

3 of Wall Street’s Favorite Stocks That Concern Us

PTLO : 5.45 (+5.21%)
TRNS : 64.40 (+1.15%)
SUPN : 51.80 (+0.68%)
1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down

1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down

OSCR : 16.69 (-3.97%)
SUPN : 51.80 (+0.68%)
PRVA : 22.85 (-0.87%)
3 Stocks Under $50 That Concern Us

3 Stocks Under $50 That Concern Us

SUPN : 51.80 (+0.68%)
PEBO : 30.85 (+1.61%)
PRDO : 30.97 (-1.99%)
3 Unprofitable Stocks We Find Risky

3 Unprofitable Stocks We Find Risky

AAP : 42.88 (+1.20%)
SUPN : 51.80 (+0.68%)
CNC : 46.17 (+0.90%)
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference

ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central...

SUPN : 51.80 (+0.68%)
1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds

COO : 81.69 (-0.01%)
SUPN : 51.80 (+0.68%)
HCA : 478.84 (-0.10%)
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference

ROCKVILLE, Md., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central...

SUPN : 51.80 (+0.68%)
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

SUPN : 51.80 (+0.68%)
3 Russell 2000 Stocks Walking a Fine Line

3 Russell 2000 Stocks Walking a Fine Line

LMAT : 85.46 (+2.54%)
SUPN : 51.80 (+0.68%)
WNC : 10.59 (+0.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit...

See More

Key Turning Points

3rd Resistance Point 54.06
2nd Resistance Point 53.13
1st Resistance Point 52.47
Last Price 51.80
1st Support Level 50.87
2nd Support Level 49.94
3rd Support Level 49.28

See More

52-Week High 57.65
Last Price 51.80
Fibonacci 61.8% 46.77
Fibonacci 50% 43.40
Fibonacci 38.2% 40.04
52-Week Low 29.16

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar